Jean-François Rossignol, Ph.D., MD
Chief Scientific Officer
University of South Florida, Morsani College of Medicine
44 U.S. Patents
Jean-François Rossignol is co-founder and Chief Scientific Officer at Romark Laboratories in Tampa as well as a professor of Medicine and Infectious Disease at the University of South Florida (USF). Born in France, Rossignol is a scientist, medical chemist, and physician who developed groundbreaking treatments for parasitic diseases and, in 1974, discovered a new class of broad spectrum antiviral drugs. After completing his medical training, he worked for the Division of Parasitic Diseases at the World Health Organization. Subsequently, he pursued a career in academia and pharmaceuticals, discovering and developing drugs such as halofantrine for the treatment of resistant falciparum malaria as well as albendazole and nitazoxanide to treat intestinal protozoan and helminthic infections. Later, while working at Stanford University, he uncovered nitazoxanide’s antiviral activity against the hepatitis C virus (HCV). Additionally, nitazoxanide, was the first treatment for cryptosporidial diarrhea and viral gastroenteritis, caused by norovirus and rotavirus, found safe enough to be given to infants. This led to the development of a new class of antiviral drugs known as thiazolides that stimulate immune cells, activating gene pathways that block viral transformation. Romark Labs have initiated the synthesis of second generation thiazolides and established new derivatives that are now entering clinical development in the treatment of rotavirus and norovirus, influenza and influenza like illnesses as well as chronic HBV and HCV. Rossignol holds 41 U.S. patents and is a fellow of the College of Physicians of Philadelphia. In 2016, he received an honorary MD from the University of South Florida.